NightHawk Biosciences (formerly known as Heat Biologics) is a clinical-stage company focused on developing its proprietary "ImPACT" (Immune Pan-Antigen Cytotoxic Therapy), a fully allogeneic (“off-the-shelf”) cell-based immunotherapy for use in the treatment of a wide range of cancers.The Company's ImPACT therapy is a first-in-class, fully human immunotherapy that functions as both an immune stimulator and an antigen-delivery system. ImPACT effectively transforms living allogeneic cells into "osmotic pumps" that continuously secrete cancerous antigens to robustly stimulate the immune system against the targeted cancer. This therapy is applicable to a wide range of cancers.Heat is currently conducting multiple clinical trials in two indications with its ImPACT therapy based products, HS-410 to treat Non-Muscle Invasive Bladder Cancer (NMIBC) and HS-110 to treat Non-Small Cell Lung Cancer (NSCLC).